Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Helus Pharma ( (HELP) ) is now available.
Helus Pharma has strengthened its senior leadership team by appointing veteran neuroscience executive Dr. Ken Kramer as Senior Vice President, Medical Affairs, adding deep medical affairs and launch experience to support its advancing neuropsychiatry pipeline. With a track record that includes leading the launch of a landmark schizophrenia treatment and building medical capabilities at major pharmaceutical companies, Kramer is expected to bolster Helus’s scientific engagement and help translate its NSA-focused research into broader clinical understanding and, ultimately, improved patient outcomes.
The move underscores Helus’s push to scale its medical infrastructure as its late-stage programs in major depressive disorder and generalized anxiety disorder progress, potentially enhancing its competitive position in the emerging field of serotonergic neuropsychiatric therapies. By bringing in a leader with extensive experience in evidence generation, KOL engagement, and global launch readiness, the company is signaling its intent to prepare for commercialization and deepen relationships with clinicians, payors, and other stakeholders in mental health care.
The most recent analyst rating on (HELP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page.
More about Helus Pharma
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists, or NSAs, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company targets large unmet needs in depression, anxiety, and other mental health conditions, with lead candidates HLP003 in Phase 3 for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, and operates across Canada, the U.S., the U.K., and Ireland.
Average Trading Volume: 797,682
Technical Sentiment Signal: Sell
Current Market Cap: $1.4M
See more insights into HELP stock on TipRanks’ Stock Analysis page.